Anti-lgE treatment in allergic disease

Allergy and Clinical Immunology International

Volumn 13, Issue 1, 2001, Pages 4-10

  Pawankar, R ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CGP 51901; GLUCOCORTICOID; HISTAMINE; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 4; MONOCLONAL ANTIBODY; OMALIZUMAB; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; ANTIGEN ANTIBODY COMPLEX; ARTICLE; ASTHMA; ATOPY; BASOPHIL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG HALF LIFE; EVALUATION; HELPER CELL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; MAST CELL; MEDIATOR RELEASE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; SIDE EFFECT; SKIN TEST; SNEEZING; SYMPTOM;

EID: 0035114603     PISSN: 08381925     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. IL-4, -5, -6 and TNF α in normal and asthmatic airways: Evidence of the human mast cell as a source of these cytokines
2. Inteleukin-13 expression in the nasal mucosa of perennial allergic rhintics
3. Interleukin-4 is localized to and released by human mast cells
4. TNF α is localized to nasal mucosal mast cells and is released in acute rhinitis
5. IgE-dependent expression of mRNA for IL-4 and IL-5 in human lung mast cells
6. Nasal mast cells exhibit increased expression of the FcεRI, CD40L, IL-4 and IL-13 and can induce IgE synthesis in B cells
7. IgE enhances mouse mast cell FcεRI expression in vitro and in vivo: Evidence for a novel amplication mechanism in IgE-dependent reactions
8. Dendritic cells in the lung - What is their relevance to asthma?
9. FcεRI-expressing antigen-presenting cells: New players in the atopic game
10. Demonstration of the high-affinity IgE receptor (FcεRI) on Langerhans' cells of diseased nasal mucosa
11. Expression and functions of the high-affinity IgE receptor on human platelets and megakaryocyte precursors
12. Functional expession of the high affinity receptor for IgE (FcεRI) in human platelets and its intracellular expression in human megakaryocytes
13. High-affinity IgE receptor on eosinophils is involved in defence against parasites
14. Expression of functional high affinity immunoglobulin E receptors (FcεRI) on monocytes of atopic individuals
15. Expression of the high-affinity receptor for IgE on bronchial epithelial cells of asthmatics
16. Nasal must cells in perennial allergic rhinitics exhibit increased expression of the FcεRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cell
17. Enhanced expression of high-affinity IgE receptor (FcεRI) α chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells
18. Expression of high-affinity IgE receptors (FcεRI) on peripheral blood basophils, monocytes, and eosinophils in atopic and nonatopic subjects: Relationship to total serum IgE concentrations
19. High-affinity immunoglobulin E receptor (FcεRI)-bearing eosinophils, mast cells, macrophages and Langerhans' cells in allergen-induced late-phase cutaneous reactions in atopic subjects
20. IgE receptors on human basophils. Relationship to serum IgE concentration
21. Comparative studies of human basophils and mast cells
22. IgE enhances mouse mast cell Fc(ε)RI expression in vitro and in vivo: Evidence for a novel amplification mechanism in IgE-dependent reactions
23. In vitro regulation of FcεRIα expression on human basophils by IgE antibody
24. Upregulation of FcεRI on human basophils by IgE antibody is mediated by interaction of IgE with FcεRI
25. Induction of the high-affinity IgE receptor (FcεRI) on human mast cells by IL-4
26. IgE-IgE receptor mast cells axis in allergy
27. The high affinity IgE receptor (FcεR1) mediates IgE-dependent allergen presentation
28. Function and regulation of FcεR1 expression on monocytes from non-atopic donors
29. IgE dependent antigen focusing by human B lymphocytes is mediated by the low affinity receptor for IgE
30. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: Inhibition by a non-anaphylactogenic anti-IgE antibody
31. Attenuation of allergic airway inflammation in IL-4 deficient mice
32. Association of asthma with serum IgE levels and skin test reactivity to allergens
33. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children
34. Concentration of Methacholine for bronchial responsiveness according to symptoms, smoking, and immunoglobulin E in population based study in Spain
35. Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits
36. IgE antibody measurements in ragweed hay fever
37. Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin E antibodies
38. Glucocorticosteroids: Their mechanisms of action and use in allergic diseases
39. Dexamethasone or cyclosporin A suppresses mast cell-leukocyte cytokine cascades
40. Humanization of a mouse anti-human IgE antibody: A potential therapeutic for IgE-mediated allergies
41. Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo
42. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics
43. Can anti-IgE be used to treat allergy
44. Pharmakokinetics and immune response of 131 I-chimeric mouse/human B72-3 (human γ4) monoclonal antibody in humans
45. The immunogenicity of chimeric antibodies
46. Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering
47. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE
48. Downregulation of Fc(ε)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody
49. Inhibition of allergic reactions with antibodies to IgE
50. Identification of γ-E antibodies as a carrier of reagenic activity
51. Immunological studies of an atypical (myeloma) immunoglobulin
52. Use of anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis
53. RhuMabE25 in the treatment of seasonal allergic rhinitis
54. RhuMabE25 improves quality of life in patients with seasonal allergic rhinitis (SAR)
55. The effect of anti-IgE monoclonal antibody on the early and late phase responses to allergen inhalation in asthmatic subjects
56. Inhibitory effects of anti-IgE monoclonal antibody E25 on allergen induced early asthmatic response
57. Treatment of allergic asthma with monoclonal anti-IgE antibody
58. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy
59. WHO Position paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases
60. Relationships between rhinitis and asthma
61. Symptom control in patients with hay fever in UK general practice: How well are we doing and is there a need for allergen immunotherapy?
62. Downregulation of human basophil IgE and FcεRIα surface densities and mediator release by Anti-IgE infusions is reversible in vitro and in vivo